Fig. 2
From: Effects of a combination treatment of KD5040 and L-dopa in a mouse model of Parkinson’s disease
Effects of combination treatment on days 2 (a), 4 (b), 6 (c), and 8 (d) after first treatment with KD5040 based on the rotarod test. The l -dopa groups (LL and ML) exhibited dose-dependent increases in latency time, and the combination treatment resulted in synergistic increases. C: control, M: MPTP, K: KD5040, LL: low dose of l -dopa (5 mg/kg), ML: medium dose of l -dopa (10 mg/kg). *** p < 0.001 compared to control, ### p < 0.001 and ## p < 0.01 compared to MPTP, and ††† p < 0.001, †† p < 0.01, and † p < 0.05 compared to each dose of l -dopa